tisotumab vedotin

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
tisotumab vedotin

GtoPdb Ligand ID: 11719

Synonyms: HuMax-TF-ADC | TF-011-MMAE | tisotumab vedotin-tftv | Tivdak®

tisotumab vedotin is an approved drug (FDA (2021))

Compound class: Antibody

Comment: Tisotumab vedotin is an antibody-drug conjugate (ADC) of an anti-factor 3 monoclonal antibody that is conjugated to the antineoplastic agent monomethyl auristatin E (MMAE; PubChem CID 11542188) [1]. Tisotumab vedotin causes adverse events that are associated with disrupted coagulation [4].

References
1. Breij EC, de Goeij BE, Verploegen S, Schuurhuis DH, Amirkhosravi A, Francis J, Miller VB, Houtkamp M, Bleeker WK, Satijn D et al.. (2014) An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res, 74 (4): 1214-26. [PMID:24371232]
2. Coleman RL, Lorusso D, Gennigens C, González-Martín A, Randall L, Cibula D, Lund B, Woelber L, Pignata S, Forget F et al.. (2021) Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol, 22 (5): 609-619. [PMID:33845034]
3. de Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels JP, Arkenau HT, Plummer R, Jones RH, Nielsen D, Windfeld K et al.. (2019) Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncol, 20 (3): 383-393. [PMID:30745090]
4. Theunissen JW, Cai AG, Bhatti MM, Cooper AB, Avery AD, Dorfman R, Guelman S, Levashova Z, Migone TS. (2018) Treating Tissue Factor-Positive Cancers with Antibody-Drug Conjugates That Do Not Affect Blood Clotting. Mol Cancer Ther, 17 (11): 2412-2426. [PMID:30126944]
5. (2021) Tisotumab Vedotin Yields Responses as Second-Line Cervical Cancer Therapy. Cancer Discov, 11 (6): 1319. [PMID:33931438]

References

1. Breij EC, de Goeij BE, Verploegen S, Schuurhuis DH, Amirkhosravi A, Francis J, Miller VB, Houtkamp M, Bleeker WK, Satijn D et al.. (2014)
An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.
Cancer Res, 74 (4): 1214-26. [PMID:24371232]

2. Coleman RL, Lorusso D, Gennigens C, González-Martín A, Randall L, Cibula D, Lund B, Woelber L, Pignata S, Forget F et al.. (2021)
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol, 22 (5): 609-619. [PMID:33845034]

3. de Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels JP, Arkenau HT, Plummer R, Jones RH, Nielsen D, Windfeld K et al.. (2019)
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
Lancet Oncol, 20 (3): 383-393. [PMID:30745090]

4. Theunissen JW, Cai AG, Bhatti MM, Cooper AB, Avery AD, Dorfman R, Guelman S, Levashova Z, Migone TS. (2018)
Treating Tissue Factor-Positive Cancers with Antibody-Drug Conjugates That Do Not Affect Blood Clotting.
Mol Cancer Ther, 17 (11): 2412-2426. [PMID:30126944]

5. (2021)
Tisotumab Vedotin Yields Responses as Second-Line Cervical Cancer Therapy.
Cancer Discov, 11 (6): 1319. [PMID:33931438]